Dataset Information

Preclinical Validation of a Single-Scan Rest/Stress Imaging Technique for ¹³N-Ammonia Positron Emission Tomography Cardiac Perfusion Studies.

ABSTRACT:

Background

We previously proposed a technique for quantitative measurement of rest and stress absolute myocardial blood flow (MBF) using a 2-injection single-scan imaging session. Recently, we validated the method in a pig model for the long-lived radiotracer ¹⁸F-Flurpiridaz with adenosine as a pharmacological stressor. The aim of the present work is to validate our technique for ¹³NH₃.

Methods

Nine studies were performed in 6 pigs; 5 studies were done in the native state and 4 after infarction of the left anterior descending artery. Each study consisted of 3 dynamic scans: a 2-injection rest-rest single-scan acquisition (scan A), a 2-injection rest/stress single-scan acquisition (scan B), and a conventional 1-injection stress acquisition (scan C). Variable doses of adenosine combined with dobutamine were administered to induce a wide range of MBF. The 2-injection single-scan measurements were fitted with our nonstationary kinetic model (MGH2). In 4 studies, ¹³NH₃ injections were paired with microsphere injections. MBF estimates obtained with our method were compared with those obtained with the standard method and with microspheres. We used a model-based method to generate separate rest and stress perfusion images.

Results

In the absence of stress (scan A), the MBF values estimated by MGH2 were nearly the same for the 2-radiotracer injections (mean difference: 0.067±0.070 mL·min^-1·cc^-1, limits of agreement: [-0.070 to 0.204] mL·min^-1·cc^-1), showing good repeatability. Bland-Altman analyses demonstrated very good agreement with the conventional method for both rest (mean difference: -0.034±0.035 mL·min^-1·cc^-1, limits of agreement: [-0.103 to 0.035] mL·min^-1·cc^-1) and stress (mean difference: 0.057±0.361 mL·min^-1·cc^-1, limits of agreement: [-0.651 to 0.765] mL·min^-1·cc^-1) MBF measurements. Positron emission tomography and microsphere MBF measurements correlated closely. Very good quality perfusion images were obtained.

Conclusions

This study provides in vivo validation of our single-scan rest-stress method for ¹³NH₃ measurements. The ¹³NH₃ rest/stress myocardial perfusion imaging procedure can be compressed into a single positron emission tomography scan session lasting less than 15 minutes.

SUBMITTER: Guehl NJ

PROVIDER: S-EPMC7205554 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Preclinical Validation of a Single-Scan Rest/Stress Imaging Technique for <sup>13</sup>N-Ammonia Positron Emission Tomography Cardiac Perfusion Studies.

Guehl Nicolas J NJ Pelletier-Galarneau Matthieu M Wooten Dustin W DW Guerrero J Luis JL Kas Aurélie A Normandin Marc D MD Fakhri Georges El GE Alpert Nathaniel M NM

Circulation. Cardiovascular imaging 20200121 1

<h4>Background</h4>We previously proposed a technique for quantitative measurement of rest and stress absolute myocardial blood flow (MBF) using a 2-injection single-scan imaging session. Recently, we validated the method in a pig model for the long-lived radiotracer <sup>18</sup>F-Flurpiridaz with adenosine as a pharmacological stressor. The aim of the present work is to validate our technique for <sup>13</sup>NH<sub>3</sub>.<h4>Methods</h4>Nine studies were performed in 6 pigs; 5 studies were ...[more]

PMID: 31959009

Similar Datasets

Project description:Rates of tau accumulation in cognitively unimpaired older adults are subtle, with magnitude and spatial patterns varying in recent reports. Regional accumulation also likely varies in the degree to which accumulation is amyloid-β-dependent. Thus, there is a need to evaluate the pattern and consistency of tau accumulation across multiple cognitively unimpaired cohorts and how these patterns relate to amyloid burden, in order to design optimal tau end points for clinical trials. Using three large cohorts of cognitively unimpaired older adults, the Anti-Amyloid Treatment in Asymptomatic Alzheimer's and companion study, Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (n = 447), the Alzheimer's Disease Neuroimaging Initiative (n = 420) and the Harvard Aging Brain Study (n = 190), we attempted to identify regions with high rates of tau accumulation and estimate how these rates evolve over a continuous spectrum of baseline amyloid deposition. Optimal combinations of regions, tailored to multiple ranges of baseline amyloid burden as hypothetical clinical trial inclusion criteria, were tested and validated. The inferior temporal cortex, fusiform gyrus and middle temporal cortex had the largest effect sizes of accumulation in both longitudinal cohorts when considered individually. When tau regions of interest were combined to find composite weights to maximize the effect size of tau change over time, both longitudinal studies exhibited a similar pattern-inferior temporal cortex, almost exclusively, was optimal for participants with mildly elevated amyloid β levels. For participants with highly elevated baseline amyloid β levels, combined optimal composite weights were 53% inferior temporal cortex, 31% amygdala and 16% fusiform. At mildly elevated levels of baseline amyloid β, a sample size of 200/group required a treatment effect of 0.40-0.45 (40-45% slowing of tau accumulation) to power an 18-month trial using the optimized composite. Neither a temporal lobe composite nor a global composite reached 80% power with 200/group with an effect size under 0.5. The focus of early tau accumulation on the medial temporal lobe has resulted from the observation that the entorhinal cortex is the initial site to show abnormal levels of tau with age. However, these abnormal levels do not appear to be the result of a high rate of accumulation in the short term, but possibly a more moderate rate occurring early with respect to age. While the entorhinal cortex plays a central role in the early appearance of tau, it may be the inferior temporal cortex that is the critical region for rapid tau accumulation in preclinical Alzheimer's disease.

Dataset Information

Preclinical Validation of a Single-Scan Rest/Stress Imaging Technique for ¹³N-Ammonia Positron Emission Tomography Cardiac Perfusion Studies.

Background

Methods

Results

Conclusions

Publications

Preclinical Validation of a Single-Scan Rest/Stress Imaging Technique for <sup>13</sup>N-Ammonia Positron Emission Tomography Cardiac Perfusion Studies.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

Preclinical Validation of a Single-Scan Rest/Stress Imaging Technique for 13N-Ammonia Positron Emission Tomography Cardiac Perfusion Studies.

Background

Methods

Results

Conclusions

Publications

Preclinical Validation of a Single-Scan Rest/Stress Imaging Technique for <sup>13</sup>N-Ammonia Positron Emission Tomography Cardiac Perfusion Studies.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Preclinical Validation of a Single-Scan Rest/Stress Imaging Technique for ¹³N-Ammonia Positron Emission Tomography Cardiac Perfusion Studies.